Alvogen today announced the appointment of Lisa Graver as President for the Americas region effective immediately. Lisa, who joined Alvogen in 2010, has served as EVP of Strategic Operations in the U.S. market for the last three years. In this role she has overseen global R&D and regulatory affairs, portfolio selection, and legal for the U.S. Under her leadership, Alvogen has built a pipeline 28 potential first-to-file/first-to-market drugs for the U.S. market and a total pipeline of over 60 ANDA‘s.
Prior to joining Alvogen, Lisa served as Vice President of Intellectual Property for Actavis. She received her JD, cum laude, from Case Western University and Honors Bachelor of Science degree from Lakehead University. In her new role, Lisa will be responsible for leading Alvogen’s U.S. business as it continues to grow its product pipeline and launch bring new products to market. The U.S. is currently Alvogen’s largest contributor to the company’s overall revenue, with primary focus on the development, manufacture, and commercialization of high value generic pharmaceuticals.
Robert Wessman, Alvogen‘s Chairman and CEO said,
“Lisa‘s rich and diverse experience in the pharmaceutical industry brings significant strategic value and leadership to Alvogen. She has played an instrumental role in building our U.S. business since 2010 and has led our R&D and regulatory teams. Her innovative approach and very strong leadership capabilities make her a true asset for Alvogen, our customers and the patients we serve. I am confident she will continue to make a significant contribution to the business in her new position. “